PubRank

Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma

Clinical Trial ID NCT02103335

PubWeight™ 7.25‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02103335

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Prediction of creatinine clearance from serum creatinine. Nephron 1976 64.02
2 International uniform response criteria for multiple myeloma. Leukemia 2006 17.78
3 Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005 15.30
4 High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003 8.93
5 Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 8.77
6 Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007 8.41
7 Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003 7.15
8 Derivation of a simple clinical model to categorize patients probability of pulmonary embolism: increasing the models utility with the SimpliRED D-dimer. Thromb Haemost 2000 4.81
9 Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010 4.52
10 Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000 4.37
11 Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol 2013 4.30
12 Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood 2011 4.00
13 Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007 3.54
14 Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002 3.01
15 Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009 2.59
16 High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005 2.35
17 Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells. Cancer Res 2003 1.70
18 Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma. Blood 2009 1.25
19 Clinical use of proteasome inhibitors in the treatment of multiple myeloma. Pharmaceuticals (Basel) 2014 0.91
20 Promising therapies in multiple myeloma. Blood 2015 0.89
21 New investigational drugs with single-agent activity in multiple myeloma. Blood Cancer J 2016 0.87
22 Targeted therapies in multiple myeloma. Target Oncol 2009 0.84
23 Methodology for a rapid protocol to rule out pulmonary embolism in the emergency department. Ann Emerg Med 2003 0.82
24 Evolving paradigms in the treatment of relapsed/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transplant 2016 0.82
25 When Cancer Fights Back: Multiple Myeloma, Proteasome Inhibition, and the Heat-Shock Response. Mol Cancer Res 2015 0.79
26 Marizomib irreversibly inhibits proteasome to overcome compensatory hyperactivation in multiple myeloma and solid tumour patients. Br J Haematol 2016 0.78
27 Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future? Onco Targets Ther 2016 0.76
28 Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. Neuro Oncol 2015 0.76
29 Trial Watch: Proteasomal inhibitors for anticancer therapy. Mol Cell Oncol 2014 0.75
Next 100